Source author record

Markus Reischl

Markus Reischl appears in the imported research catalog. Authorship, coauthor and topic links are available while profile ownership is still unclaimed.

ResearcherUnclaimed source record

Catalog footprint

What is connected

2works
3topics
4close collaborators

Actions

Connect this record

Log in to claim

Research graph

See the researcher in context

Open full explorer

Inspect adjacent papers, topics, institutions and collaborators without losing the researcher page.

Building this map preview

BZPEER is loading the nearby papers, people, topics and institutions for this page.

Published work

2 published item(s)

preprint2022arXiv

ciscNet -- A Single-Branch Cell Instance Segmentation and Classification Network

Automated cell nucleus segmentation and classification are required to assist pathologists in their decision making. The Colon Nuclei Identification and Counting Challenge 2022 (CoNIC Challenge 2022) supports the development and comparability of segmentation and classification methods for histopathological images. In this contribution, we describe our CoNIC Challenge 2022 method ciscNet to segment, classify and count cell nuclei, and report preliminary evaluation results. Our code is available at https://git.scc.kit.edu/ciscnet/ciscnet-conic-2022.

preprint2016arXiv

Robust Individual Circadian Parameter Estimation for Biosignal-based Personalisation of Cancer Chronotherapy

In cancer treatment, chemotherapy is administered according a constant schedule. The chronotherapy approach, considering chronobiological drug delivery, adapts the chemotherapy profile to the circadian rhythms of the human organism. This reduces toxicity effects and at the same time enhances efficiency of chemotherapy. To personalize cancer treatment, chemotherapy profiles have to be further adapted to individual patients. Therefore, we present a new model to represent cycle phenomena in circadian rhythms. The model enables a more precise modelling of the underlying circadian rhythms. In comparison with the standard model, our model delivers better results in all defined quality indices. The new model can be used to adapt the chemotherapy profile efficiently to individual patients. The adaption to individual patients contributes to the aim of personalizing cancer therapy.